Innocare Pharma
Innocare Pharma, a leading biopharmaceutical company headquartered in China (CN), is dedicated to advancing innovative therapies in the oncology and autoimmune disease sectors. Founded in 2015, the company has rapidly established itself as a key player in the industry, focusing on the development of novel treatments that address unmet medical needs. With a robust pipeline of targeted therapies and monoclonal antibodies, Innocare Pharma distinguishes itself through its commitment to research and development, leveraging cutting-edge technology to enhance patient outcomes. The company has achieved significant milestones, including successful clinical trials and strategic partnerships, solidifying its position in the global market. As Innocare Pharma continues to expand its operational reach, it remains focused on delivering high-quality, effective solutions that improve the lives of patients worldwide.
DitchCarbon Score
How does Innocare Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Innocare Pharma's score of 21 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Innocare Pharma's reported carbon emissions
Innocare Pharma's carbon emissions data for 2022 indicates a total of approximately 9,835,800 kg CO2e, comprising solely Scope 2 emissions, as there were no reported Scope 1 emissions. This figure reflects a significant increase from 2021, where emissions were about 9,236,400 kg CO2e, also entirely from Scope 2. In 2020, the company reported approximately 2,476,590 kg CO2e, again limited to Scope 2 emissions. Despite the increase in emissions over the past two years, Innocare Pharma has not disclosed any specific reduction targets or initiatives aimed at mitigating their carbon footprint. The absence of data on Scope 3 emissions suggests a potential area for future focus, as these often represent a substantial portion of a company's overall emissions. Innocare Pharma's emissions data is not cascaded from any parent organization, indicating that the figures are independently reported. The company has not committed to any industry-standard climate initiatives such as the Science Based Targets initiative (SBTi) or similar pledges. Overall, while Innocare Pharma has made strides in reporting its emissions, the lack of reduction targets and the increase in emissions highlight the need for a more robust climate strategy moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | - | - | - |
| Scope 2 | 2,476,590 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Innocare Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
